Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab

ctDNA profiling may provide a benefit for prediction of survival and progression of HCC patients treated with nivolumab. Future studies are needed for confirmation.

Authors

Institutions

Publication Details

Journal
Cancer Biomarkers
Published
2024-09-01
DOI
https://doi.org/10.3233/cbm-230431
Citations
9
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
2.57

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab

Jeffrey S. Morris, Hesham M. Amin, Armeen Mahvash, Tarık Demir et al.
9 citations
Cancer Biomarkers
Cancer Genomics and Diagnostics
2.57
article

Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab

Jeffrey S. Morris, Hesham M. Amin, Armeen Mahvash, Tarık Demir, Shadi Chamseddine, Michael LaPelusa, Dan G. Duda, Eugene J. Koay, Robert A. Wolff, James C. Yao, Ahmed Omar Kaseb, Aliya Qayyum, Sunyoung S. Lee, Khaled M. Elsayes, Ahmed Azzam, Lianchun Xiao, Zishuo Ian Hu, Yehia I. Mohamed, Rikita Hiatia, Asif Rashid, Ecaterina E Ileana Dumbrava, Manal M. Hassan
article en
9 citations

Abstract

ctDNA profiling may provide a benefit for prediction of survival and progression of HCC patients treated with nivolumab. Future studies are needed for confirmation.

Cancer BiomarkersVol. 41(1)
The University of Texas MD Anderson Cancer Center (US), Harvard University (US), California University of Pennsylvania (US), Massachusetts General Hospital (US), University of Pennsylvania (US), The University of Texas at Austin (US), The University of Texas Health Science Center at Houston (US)
U.S. Department of Defense, National Institutes of Health, University of Texas MD Anderson Cancer Center, National Cancer Institute, DOD Peer Reviewed Cancer Research Program
Good health and well-being
Openalex Percentile: Top 9%
Cancer Genomics and Diagnostics
2.57
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.